| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Soyasaponin III induces apoptosis in cancer cells, specifically in Hep-G2 human liver cancer cells. It exhibits antioxidant, anti-inflammatory, and antimicrobial activities. The compound may modulate cholesterol levels, supporting cardiovascular health. It may enhance the immune system and support gut health by acting as a prebiotic. As a triterpenoid saponin, it interacts with cell membranes and modulates various cellular signaling pathways involved in apoptosis and inflammation.
|
|---|---|
| ln Vitro |
Soyasaponin III demonstrates potent in vitro anticancer activity by inducing apoptosis in Hep-G2 human liver cancer cells. The compound exhibits significant cytotoxicity in Hep-G2 cells, making it a valuable tool for research into cancer biology. It shows antioxidant, anti-inflammatory, and antimicrobial properties in various in vitro assays. The compound's ability to induce apoptosis has been extensively studied, revealing its potential as an anticancer agent. It regulates gene expression and modulates cell proliferation and differentiation.
|
| ln Vivo |
Soyasaponin III has demonstrated in vivo activity in various disease models. It shows promise in anticancer research by inhibiting tumor growth. The compound may support cardiovascular health by improving cholesterol levels. Its anti-inflammatory properties contribute to protective effects in inflammatory disease models. The compound may enhance immune function and support gut health through prebiotic activity. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profile across different disease indications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Soyasaponin III typically involve investigating its interactions with various molecular targets. For apoptosis studies, caspase activity assays are performed using recombinant caspases and fluorogenic substrates (e.g., Ac-DEVD-AMC for caspase-3). The compound is incubated with caspase and substrate in assay buffer at 37°C, and fluorescence is measured over time. For anti-inflammatory studies, NF-κB activation can be assessed using electrophoretic mobility shift assays (EMSA) with nuclear extracts. Antioxidant activity is evaluated using DPPH radical scavenging, ABTS, or FRAP assays. Enzyme inhibition studies (e.g., for enzymes involved in cholesterol metabolism) are performed with various concentrations of the compound to determine IC₅₀ values.
|
| Cell Assay |
For in vitro cell-based assays, Hep-G2 human liver cancer cells are cultured in appropriate media supplemented with fetal bovine serum and antibiotics. Cells are treated with Soyasaponin III at concentrations ranging from 1-200 μM for 24-72 hours. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V-FITC/PI double staining flow cytometry, caspase-3/9 activity assays, and Western blot analysis of apoptotic markers (Bax, Bcl-2, cleaved PARP). DNA fragmentation is assessed by TUNEL assay. For anti-inflammatory studies, immune cells are stimulated with LPS with or without compound pretreatment, and cytokine levels are measured by ELISA. Cell cycle analysis is performed by propidium iodide staining and flow cytometry.
|
| Animal Protocol |
In vivo animal studies with Soyasaponin III typically use mouse or rat models for various disease indications. For anticancer studies, immunodeficient mice are subcutaneously implanted with cancer cells (e.g., Hep-G2) to establish xenograft tumors. The compound is administered orally or intraperitoneally at doses ranging from 5-50 mg/kg daily or every other day for 2-4 weeks. Tumor volume and body weight are monitored regularly. At study endpoint, tumors are excised, weighed, and processed for histopathological and molecular analyses (TUNEL, immunohistochemistry for apoptotic markers). For cholesterol studies, animals are fed a high-fat diet with or without compound supplementation, and serum lipid profiles are measured. Tissue samples are collected for histology and biochemical analysis.
|
| ADME/Pharmacokinetics |
Soyasaponin III has a molecular weight of 796.99 g/mol and molecular formula C₄₂H₆₈O₁₄. The compound has a predicted relative density of 1.37 g/cm³. Storage recommendations are powder at -20°C for 3 years and in solvent at -80°C for 1 year. As a saponin, the compound has poor oral bioavailability due to its high molecular weight and polarity, requiring formulation strategies for in vivo administration. Saponins are generally metabolized by gut microbiota, and the aglycone metabolites may contribute to the overall pharmacological activity.
|
| Toxicity/Toxicokinetics |
Soyasaponin III is considered to have a favorable safety profile as a naturally occurring saponin found in soy and related legumes, which have a long history of dietary consumption. In preclinical studies, the compound has shown no significant toxicity at pharmacologically relevant doses. As a saponin, high doses may cause gastrointestinal effects including mild irritation of the gastric mucosa, which is characteristic of this class of compounds. The compound's antioxidant and anti-inflammatory properties may provide protective effects. No specific toxicity data are available for pure Soyasaponin III.
|
| References | |
| Additional Infomation |
Soyasaponin III is a major bioactive saponin found in soy (Glycine max) and related products. It is a monodesmodic oleanane triterpenoid saponin. The compound has been studied for its potential in cancer research, cardiovascular health, and immune modulation. It can induce apoptosis in Hep-G2 cells and shows antioxidant, anti-inflammatory, and antimicrobial properties. The compound may act as a prebiotic to support gut health. Soyasaponin III is not approved as a therapeutic drug and is intended for research purposes only.
|
| Molecular Formula |
C42H68O14
|
|---|---|
| Molecular Weight |
796.980920000001
|
| Exact Mass |
796.461
|
| CAS # |
55304-02-4
|
| PubChem CID |
13326389
|
| Appearance |
White to off-white solid powder
|
| Density |
1.37 g/cm3
|
| Boiling Point |
910.8ºC at 760 mmHg
|
| Melting Point |
215 - 216 °C
|
| Flash Point |
267.8ºC
|
| Index of Refraction |
1.615
|
| LogP |
1.852
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
56
|
| Complexity |
1520
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OKIHRVKXRCAJFQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H68O14/c1-37(2)16-21-20-8-9-24-39(4)12-11-26(40(5,19-44)23(39)10-13-42(24,7)41(20,6)15-14-38(21,3)25(45)17-37)54-36-33(30(49)29(48)32(55-36)34(51)52)56-35-31(50)28(47)27(46)22(18-43)53-35/h8,21-33,35-36,43-50H,9-19H2,1-7H3,(H,51,52)
|
| Chemical Name |
3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~62.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2547 mL | 6.2737 mL | 12.5474 mL | |
| 5 mM | 0.2509 mL | 1.2547 mL | 2.5095 mL | |
| 10 mM | 0.1255 mL | 0.6274 mL | 1.2547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
